Sign In
Buy ADXS
$0.604
+0 (+0%)
At Close: May 01, 2026
Aadi Bioscience (NASDAQ:AADI) and Ayala Pharmaceuticals (NASDAQ:ADXS) Head to Head Analysis
01:28am, Saturday, 28'th Mar 2026
Insider and Institutional Ownership 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 0.6%
Head-To-Head Survey: Evofem Biosciences (NASDAQ:EVFM) and Ayala Pharmaceuticals (NASDAQ:ADXS)
02:50am, Thursday, 26'th Mar 2026
Valuation and Earnings This table compares Ayala Pharmaceuticals and Evofem Biosciences"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
07:40am, Wednesday, 09'th Apr 2025
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today anno
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
04:10pm, Thursday, 09'th May 2024
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
08:00am, Tuesday, 26'th Mar 2024
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sal
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
07:00am, Monday, 23'rd Oct 2023
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
08:00am, Thursday, 19'th Oct 2023
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger wit
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
04:30pm, Thursday, 10'th Aug 2023
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Defin
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
08:00am, Tuesday, 01'st Aug 2023
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it wi
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
08:10am, Thursday, 27'th Jul 2023
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala's portfolio with data anticipated in the first half of 2024 REHOVOT and TEL AVIV, Isra
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
05:00pm, Thursday, 26'th May 2022
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® (p
Stock on the Move: SuperCom Ltd. (NASDAQ:SPCB), Advaxis, Inc. (NASDAQ:ADXS)
06:36am, Friday, 11'th Mar 2022 Stock Equity
SuperCom Ltd. (NASDAQ:SPCB) with the stream of 1.39% also noticed, India Advaxis, Inc. (NASDAQ:ADXS) encountered a rapid change of 9.71% in the last hour of Thursday’s trading session. SuperCom Ltd. … The post Stock on the Move: SuperCom Ltd. (NASDAQ:SPCB), Advaxis, Inc. (NASDAQ:ADXS) appeared first on Stocks Equity .
Hooky Stock: Advaxis, Inc. (NASDAQ:ADXS), Indonesia Energy Corporation Limited (AMEX:INDO)
04:13am, Tuesday, 08'th Mar 2022 Stock Equity
Advaxis, Inc. (NASDAQ:ADXS) with the stream of -17.43% also noticed, India Indonesia Energy Corporation Limited (AMEX:INDO) encountered a rapid change of 50.85% in the last hour of Monday’s trading session. … The post Hooky Stock: Advaxis, Inc. (NASDAQ:ADXS), Indonesia Energy Corporation Limited (AMEX:INDO) appeared first on Stocks Equity .
